Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Patient Insights into the Design of Technology to Support a Strengths-Based Approach to Health Care.

Greater intake of dietary omega-3 fatty acids associated with lower risk of diabetic retinopathy

SURVEY: Weight Management & Chronic Illness

Japanese green tea consumers have reduced risk of dementia

Researchers find herpes strain in the nervous system

Do Nothing, Accomplish Everything! The Connection Between Breathing and Healing

Nature Heals

Best Herbs to Help With Insomnia

Meet the ProHealth Editors

Choline: Why You Should Eat Your Egg Yolks and Take Krill

 
Print Page
Email Article

Clinical Results Suggest Drug Could Rival COX-2 Inhibitors in Treating Osteoarthritis

  [ 92 votes ]   [ Discuss This Article ]
www.ProHealth.com • June 21, 2002




The results of the first phase III clinical trials for the new osteoarthritis drug licofelone, have shown comparable efficacy to conventional NSAIDs but with excellent gastrointestinal (GI) and general tolerability. These results are similar to those achieved in the original development of COX-2 inhibitors; however, the action of licofelone should also avoid the possible disadvantages of COX-2 inhibitors and may therefore offer additional benefits for the treatment of osteoarthritis (OA).

According to data presented at the 2002 European League Against Rheumatism (EULAR) congress in Stockholm, licofelone inhibits both 5-LOX and COX enzymes in the inflammatory pathway and appears in theory, and now in clinical trials, to offer benefits over selective COX-2 inhibitors in the treatment of osteoarthritis. The most recent data presented by Professor Jean-Yves Reginster, of the University of Liege, Belgium, show licofelone to be as effective as the traditional NSAID, naproxen and with excellent GI and general tolerability.

"The trials in which we were involved start to show that our expectations for the benefits of 5-LOX/ COX inhibitors in treating osteoarthritis are well founded. Licofelone appears to offer comparable efficacy to the highly effective treatment naproxen, but with excellent GI, renal, hepatic and general tolerability," Reginster said.

Current treatment options for the inflammation and pain of osteoarthritis include conventional NSAIDs (such as the naproxen used in this study) and selective COX-2 inhibitors. Conventional NSAIDs effectively inhibit the COX-1 and COX-2 pathway, but have a high risk of adverse GI events. Selective COX-2 inhibitors have remained the main focus of research due to their early success and major pharmaceutical backing. Currently available COX-2 inhibitors have also demonstrated a reduction in gastrointestinal effects compared with the traditional NSAIDs.

However, it is now becoming clear that some COX-2 inhibitors may also be associated with an increased risk of GI events, and it is now being suggested, through the development of licofelone, that the balanced inhibition of the 5-LOX and COX pathways may provide a new alternative with an optimal benefit/risk ratio.

Professor Stefan Laufer, University of Tuebingen, Germany who is the researcher credited with discovering licofelone commented, “An extensive, published, pre-clinical program has demonstrated the anti-inflammatory and analgesic efficacy of licofelone. These results are now being confirmed in phase III studies, the first of which have been presented today. Licofelone has passed the stage of being interesting research and has now become a real potential alternative in optimizing the future treatment of osteoarthritis. We look forward to seeing the next available data which we hope will further support these findings and allow the companies involved to make a license submission to support the availability of the treatment for clinicians use as soon as possible."





Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength Energy NADH™ 12.5mg Ultra EPA  - Fish Oil

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

"It's Not Easy Being Green" - But It Is Healthy
Looking for Energy? Turn to Plants. Looking for Energy? Turn to Plants.
Nutrients to Combat the Modern Stress Epidemic Nutrients to Combat the Modern Stress Epidemic
Milk Thistle: Trusted Support for Health & Healing in a Toxic World Milk Thistle: Trusted Support for Health & Healing in a Toxic World
Improve Cardiovascular and Metabolic Health with Omega-7 Improve Cardiovascular and Metabolic Health with Omega-7

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map